摘要
目的探讨紧密连接蛋白-1(ZO-1)基因启动子区甲基化状态在非霍奇金淋巴瘤(NHL)检测中的临床意义。方法采用甲基化特异性PCR方法(MS-PCR)分析10例非血液系统肿瘤者骨髓及45例NHL患者骨髓标本的ZO-1基因启动子区甲基化状况。结果ZO-1基因在10例良性血液病及正常人中呈完全非甲基化状态,在39例初治、复发、未完全缓解的淋巴瘤患者中甲基化阳性率53.85%(P<0.05)。在39例初治或复发或未达到完全缓解的NHL患者中28例Ⅲ、Ⅳ期的NHL患者ZO-1基因甲基化阳性率64.29%,11例Ⅰ、Ⅱ期的NHL患者ZO-1基因甲基化阳性率27.27%(P<0.05)。初治、复发患者28例中甲基化阳性16例(57.14%),经治疗达到部分缓解的11例患者中甲基化阳性5例(45.45%),临床缓解的6例患者均为完全非甲基化。结论ZO-1基因启动子区高甲基化与疾病分期及缓解明显相关,它可以作为判断NHL进展和评价预后的辅助指标,并以此指导临床治疗。
Objective To investigate the methylation status of ZO-1 gene promotor in non-Hodgkin lymphoma （NHL） and its clinical significance. Methods Methylation specific PCR （MS-PCR） was used to detect the bone marrow specimen that including 40 eases of NHL and 10 cases of benign hematological diseases. Results No ZO-1 promoter methyla- tion was detected in healthy controls and benign blood diseases group. 53.85% NHL （including initial treatment, recurrence, non-complete remission） patients were found ZO-1 gene promoter in bone marrow harboring aberrant methylation （P 〈 0.05）. The methylation positive ratio of ZO-1 gene promoter in stage Ⅲ, Ⅳand Ⅰ , Ⅱ of NIH was 64.2% and 27.27% repectively （P 〈 0.05 ）. In 28 initial treatment and recurrent patients, the aberrant methylation occurred in 16 eases （57.14%） ; and as for 11 cases of patients with partial remission, 5 cases showed methylation-positive （45.45%） ; 6 eases of complete remission patients were completely non-methylated. Conclusion Hypermethylation of ZO-1 gene has a significant correlation with the stage and remission of NIH, which can be used to judge the prognosis of NHL.
出处
《山东医药》
CAS
北大核心
2010年第8期26-28,共3页
Shandong Medical Journal
基金
973国家重点基础研究专项经费项目(2005CB522400)
